Abstract: Gas and gaseous precursor filled microspheres, and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics.

Abstract: Provided herein is a method of administering a liposome composition to an animal, the method involving adminstering to the animal a liposome composition containing an adverse physiological reaction-reducing effective amount of a liposome which has, in addition to a bioactive agent, a lipid bilayer containing a lipid and a surface agent-modified molecule. An adverse physiological reaction which may be experienced by the animal upon administration of a liposome composition is reduced by way of the presence of the surface agent-modified molecule in the liposome's lipid bilayer.

Abstract: Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain laminarized surfactants and, optionally, hydrophilic stabilizers. The laminarized surfactants can be in the form of liposomes. The suspensions are obtained by exposing the laminarized surfactants to air or a gas before or after admixing with an aqueous phase.

Abstract: A method is described of immunizing a host by administering a biologically effective amount of a protein- or peptide-cochleate comprising at least a protein or peptide to which an immune response is elicited, a negatively charged lipid, and a divalent cation.

Abstract: Detectably labelled annexines and compositions thereof are disclosed. Also disclosed are methods for diagnosing a disruption or activation of the hemostatic system or a prothrombotic state in an individual suspected of having a hemostatic disorder, by contacting the blood of said individual with an annexine, and detecting whether an annexine-platelet complex is formed.

Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.

Abstract: This invention relates to tissue specific acoustically reflective oligolamellar liposomes containing internally separated bilayers and methods to make and to use the same, alone as a perfusion ultrasonic contrast agent or conjugated to a ligand for tissue-specific ultrasonic image enhancement.

Abstract: Recognizing substances, including epidermal growth factor, gelatin, collagen and hyaluronic acid, have been covalently bound to liposomal surfaces and utilized to attach liposomes onto a cellular or an extracellular matrix (ECM) target site. These "bioadhesive" liposomes offer several advantages including the mutual protection of both the drug and biological environment; an increase in drug bioavailability and retention at the target site; and improved adherence or adhesion to the designated target site.

Abstract: Liposomes of a size of less than 200 nanometers target ischemic myocardial tissue and preferentially deliver active agents to infarcted areas.

Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.

Abstract: Liposome and lipidic particle formulations of compounds are prepared by dissolving in a solution of liposome-forming lipids in an aprotic solvent such as DMSO, optionally containing a lipid-solubilizing amount of a lower alkanol, and either injecting the resulting solution into an aqueous solution, or the aqueous solution into the resulting solution. The resulting liposome or lipidic particle suspension may then be dialyzed or otherwise concentrated. This method is particularly useful for compounds which are poorly-soluble in aqueous solution, but is generally useful for any compound or combination of compounds which can be dissolved in the aprotic solvent or aprotic solvent/lower alkanol mixture.

Abstract: Liposome and lipidic particle formulations of compounds are prepared by dissolving in a solution of liposome-forming lipids in an aprotic solvent such as DMSO, optionally containing a lipid-solubilizing amount of a lower alkanol, and either injecting the resulting solution into an aqueous solution, or the aqueous solution into the resulting solution. The resulting liposome or lipidic particle suspension may then be dialyzed or otherwise concentrated. This method is particularly useful for compounds which are poorly-soluble in aqueous solution, but is generally useful for any compound or combination of compounds which can be dissolved in the aprotic solvent or aprotic solvent/lower alkanol mixture.

Abstract: WB2663 substance-producing bacteria belonging to the genus Pseudomonas are cultured to produce a physiologically active substance, from which are isolated neutral substances WB2663A, WB2663B and WB2663C having respective specific rotations[.alpha.].sub.D.sup.23 : -36.degree. (C=0.5, CH.sub.2 Cl.sub.2),[.alpha.].sub.D.sup.23 : -12.degree. (C=0.5, CH.sub.2 Cl.sub.2),[.alpha.].sub.D.sup.23 : -9.degree. (C=0.5, CH.sub.2 Cl.sub.2),These substances have an excellent antitumor effect.

Abstract: The present invention provides novel lipophilic drug derivatives which are capable of being formulated in liposomes or micelles. These drug derivatives are known therapeutic agents which are covalently attached to a fatty acid chain of a phospholipid, glyceride, ceramide or 1,2-diacyloxypropane-3-amine. The linkage between the therapeutic agent and the lipid is one which can be cleaved in vivo, allowing the therapeutic agent to be separated from the micellar or liposomal formulation.

Abstract: Liposomes of a size of less than 200 nanometers target ischemic myocardial tissue and preferentially deliver active agents to infarcted areas in the absence of antibodies bound to the liposomes to effect the delivery.

Abstract: Polymerized liposome particles based upon lipids having a polymerizable functional group and a metal chelator to attach an imaging enhancement agent and lipids having an active targeting group to provide targeted polymerized liposome contrast agents. The polymerized imaging enhancement liposome particles interact with receptor targets holding the image enhancement agent to specific sites providing in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology.

Abstract: Liposomal N,N,N-Trimethylsphingosine and pharmaceutical compositions comprising same.

Abstract: Liposome-encapsulated opioid analgesic agents delivered by the pulmonary route provide local, or systemic analgesia superior to that produced by the solution form of these agents administered by parentral (intravenous, intramuscular, or subcutaneous injection) or oral routes.

Abstract: Micellular particles such as small unilamellar vesicles of less than 2000 .ANG. loaded with .sup.111 In are administered to BALB/c mice in which EMT6 tumors had been induced. Whole body scintographs of the mice to which either neutral or positively or negatively charged vesicles had been administered show a substantial quantity of the vesicle entrapped .sup.111 In localized in the tumor. Blocking of macrophages in the liver and spleen by first administering unlabeled, aminomannose substituted vesicles before administration of the labeled vesicles increases uptake of the .sup.111 In labeled vesicles in the tumor.

Abstract: A composition having equal to or greater than about 97 percent by weight phosphatidylcholine and about equal to or less than about 3 percent by weight to about 0.5% sphingomylin and equal to or less than about 0.5% lysophosphatidylcholine (undetectable by UV at 205 nm) has been found to result in liposomes having improved stability. Methods for preparing the composition are disclosed whereby the phospholipids are extracted and then purified using silica chromatography.

Abstract: A certain fermentation product of Actinomadura strain Q473-8 yield, when suitably treated, a novel compound having both antibiotic and antitumor activities.

Abstract: Disclosed are active compounds BU-4726G-A and BU-4726G-B which contain a quinone chromophore and hydroquinone chromophore, respectively. The compounds are produced by fermentation of Streptomyces exfoliatus AA4510. The compounds possess antimicrobial, and K.sub.ATP channel blocking activities.

Abstract: Liposomes with hyperosmotic concentration of compounds encapsulated therein are targeted to tumors for neutron capture therapy. The compounds have an element with a large neutron capture cross section and an isotope that emits alpha particles when bombarded with neutrons. A method employing such liposomes for neutron capture therapy is also described.

Abstract: A certain fermentation product of Actinomadura strain Q473-8 yields, when suitably treated, a novel compound having both antibiotic and antitumor activities.

Abstract: Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to compositions comprising a mixture of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.

Abstract: A certain fermentation product of Actinomadura strain Q473-8 yields, when suitably treated, a novel compound having both antibiotic and antitumor activities.

Abstract: An automotive battery convenience pouch is provided and consists of a box like housing formed of heat resistant thermal retaining material to help increase the life span of the automotive battery. Handles are disposed on the side walls and top wall of the housing so that a person can mount the automotive battery into an awkward position and carry the housing with one hand. A modification includes a slide fastener, terminal scrapers and a removable handle.

Abstract: This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F2924.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Abstract: The present invention relates to the use of microbiologically prepared compounds and their mixtures, which are called efomycins, as performance promoters in farm animals and processes for their preparation, and furthermore new efomycins and their mixtures as new chemical compounds. The invention also relates to microorganisms which can be used for the preparation of the efomycins and their mixtures.

Abstract: A new species of Micromonospora, in particular Micromonospora spartanea ATCC 53803, is described. The species produces antifungal compounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The compounds contain deoxy-L-fucose, as well as another hexose and an amino sugar.

Abstract: A new species of Micromonospora, in particular Micromonospora spartanea ATCC 53803, is described. The species produces new antifungal compounds spartanamicins A and B. Methods for the production, isolation and characterization of the compounds are described. The new compounds contain spartanose, which is a new hexose sugar, as well as another hexose and an amino sugar.

Abstract: A test reagent for detecting fibrin monomers in blood, comprises an antibiotic of a pyrrole amidine series as a precipitant, introduced in a buffer solution. A method of detecting fibrin monomers in blood, comprises the steps of mixing venous blood with an anticoagulant, centrifuging the mixture of the venous blood with the anticoagulant, removing a citrate plasma, using an antibiotic of a pyrrole amidine series as a precipitant, and evaluating a precipitation reaction which takes place thereby.

Abstract: This invention provides particle compositions possessing ferromagnetic, paramagnetic or diamagnetic properties. The particles are especially useful when used in the disease diagnostic and treatment regimens as described in U.S. Pat. Nos. 4,106,448, 4,136,683 and 4,303,636.

Abstract: A novel antibiotic for combating bacteria and promoting animal growth is obtained by cultivating Streptomyces strain BA 9.

Abstract: Novel antibiotics didemnins A, B and C (didemnins), and nordidemnins A, B and C (nordidemnins) which can be obtained from a marine organism. These antibiotics are active against a variety of DNA and RNA viruses; thus, they can be used in various environments to control or eradicate these viruses. Further, these antibiotics can be used to treat animals and humans hosting a neoplastic disease.

Abstract: Macbecin derivatives are produced by cultivating a microorganism of the genus Actinosynnema in a culture medium.The Macbecin derivatives are useful as antibacterial, antifungal or antiprotozoal agent.

Abstract: This invention relates to K-41.C(2) esters, miticidal compositions comprising K-41.C(2) esters and anti-coccidial compositions comprising K-41.C(2) esters.

Abstract: Macbecin derivatives are produced by cultivating a microorganism of the genus Actinosynnema in a culture medium.The Macbecin derivatives are useful as antibacterial, antifungal or antiprotozoal agent.

Abstract: Synergistic activity against Candida albicans and Trichomonas vaginalis is obtained when an antifungal imidazole is combined with an antimicrobial agent selected from the group anisomycin, ascomycin, azalomycin F, brefeldin A, copiamycin, EM4940A, or EM4940B.

Abstract: Antibiotic substance named saframycin S having antibacterial activities and produced by decyanating antibiotic saframycin A or cultivating Streptomyces lavendulae strain No. 314 and recovering saframycin S from a cultured broth.

Abstract: A novel antibiotic substance, named "Mycoplanecin", of presently unknown structural formula, is produced by cultivating a Mycoplanecin-producing microorganism of the genus Actinoplanes, especially the Actinoplanes nov. sp. Strain No. 41042, NRRL No. 11462.

Abstract: Method and compositions for treatment of swine dysentery with antibiotic A-32887 (K-41). Antibiotic A-32887 is produced by submerged aerobic fermentation of Streptomyces albus NRRL 11109.

Abstract: Novel antibiotic U-62,162 producible in a fermentation under controlled conditions using a man-made biologically pure culture of the microorganism Streptomyces verdensis, Dietz and Li sp.n., NRRL 12256. This antibiotic is strongly active against various Gram-positive bacteria, for example, Staphylococcus aureus. Thus, antibiotic U-62,162 can be used in various environments to eradicate or control such bacteria.

Abstract: Novel antibiotic U-60, 394 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces woolenses, Dietz and Li sp.n., NRRL 12113. This antibiotic is strongly active against various Gram-positive bacteria, for example, Staphylococcus aureus and Streptococcus hemolyticus. It is also strongly active against the Gram-negative bacterium Streptococcus pneumoniae. Thus, antibiotic U-60, 394 can be used in various environments to eradicate or control such bacteria.

Abstract: Methods and compositions for treatment of coccidiosis in poultry with antibiotic A-32887 (K-41). Antibiotic A-32887 is produced by submerged aerobic fermentation of Streptomyces albus NRRL 11109.

Abstract: A novel microorganism species belonging to the genus Micromonospora, i.e. Micromonospora sp. A 11725 is found to be capable of producing novel macrolide antibiotics A 11725 I, A 11725 II and A 11725 III. Novel antibiotics A 11725 Ia and A 11725 IIa are also found to be derived by chemical modification of the antibiotics A 11725 I and A 11725 II, respectively. All of these antibiotics or salts thereof exhibit excellent antibacterial and anti-mycoplasmal activities against various microorganisms such as Staphylococcus or Mycoplasma, and therefore useful for various purposes including medicaments.

Abstract: A method of treating inflammation comprising topical administration to mammals suffering from an inflammatory condition not associated with amicrobial component, employing selected antibiotics as the anti-inflammatory agent.

Abstract: Antibiotic X-14868A having the following chemical structure ##STR1## and the pharmaceutically acceptable salts thereof is presented. Also presented is a fermentative method of producing the above antibiotic.Antibiotic X-14868A exhibits anticoccidiostatic activity.

Abstract: Novel rifamycin compounds, designated P, Q, R and U, produced by the fermentation of mutant strains of Streptomyces mediterranei.

Abstract: Antibiotic substances named saframycins A, B, C, D and E having antibacterial activity and activity against transplantable tumors. It is produced by cultivation of Streptomyces lavendulae strain No. 314.